News Releases
In this section
-
May 20, 2019--ARIKAYCE Plus Guideline-Based Therapy (GBT) Associated with Significantly Higher Rates of Sustained Culture Conversion on Therapy and Durable Culture Conversion Three Months Post-Treatment Compared with GBT Alone--
Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today presented new data from the ongoing...
-
May 7, 2019-- ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $21.0 Million for the First Quarter of 2019 --
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the...
-
Apr 30, 2019
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first...
-
Apr 9, 2019--Patent is 10th Issued in the U.S. for ARIKAYCE and Second Extending Patent Protection into 2035--
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the U.S. Patent and...
-
Apr 8, 2019--ARIKAYCE Preliminary U.S. Net Product Sales Approximately $21.0 Million for the First Quarter of 2019--
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the U.S. launch of...
-
Apr 2, 2019
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement...
-
Apr 1, 2019--Sustainability and Durability Data from Phase 3 CONVERT Study of ARIKAYCE to be Presented in Late-Breaking Oral Session--
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that new Phase 3 data for...
-
Apr 1, 2019
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and...
-
Mar 27, 2019
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Paolo Tombesi, Chief...
-
Mar 4, 2019
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement...
Contact Us
